key: cord-0965118-w5nhgc1e
authors: Rodrigues, Charlene M.C.; Pinto, Marta V.; Sadarangani, Manish; Plotkin, Stanley A.
title: Whither vaccines?
date: 2017-06-30
journal: Journal of Infection
DOI: 10.1016/s0163-4453(17)30184-6
sha: 2dc031b8f66e1770ed3699bb6ecbee2c53aa98d6
doc_id: 965118
cord_uid: w5nhgc1e

Summary Currently used vaccines have had major effects on eliminating common infections, largely by duplicating the immune responses induced by natural infections. Now vaccinology faces more complex problems, such as waning antibody, immunosenescence, evasion of immunity by the pathogen, deviation of immunity by the microbiome, induction of inhibitory responses, and complexity of the antigens required for protection. Fortunately, vaccine development is now incorporating knowledge from immunology, structural biology, systems biology and synthetic chemistry to meet these challenges. In addition, international organisations are developing new funding and licensing pathways for vaccines aimed at pathogens with epidemic potential that emerge from tropical areas.

Vaccination has been described as the single most important health intervention in human history. From the fi rst smallpox vaccine conceived by Jenner in 1798 1 developing the idea of attenuation to the reverse vaccinology derived capsular group B meningococcal protein vaccines, 2 the requirement for protective, long-lasting host immune responses to vaccine antigens that are safe to handle and administer with broad coverage has been the aim. To deliver these requirements, the next generation of vaccine development is drawing on major scientifi c advances in microbiology, structural biology, immunology and most recently molecular biology. However, despite the huge success of vaccinology to date, many challenges remain involving scientifi c, fi nancial, political and social domains.

Here we discuss a range of these with examples impacting on child health.

Seasonal infl uenza epidemic infections are commonly caused by infl uenza types A and B. Vaccination continues to be one of the most effi cacious ways to prevent disease, reducing morbidity and mortality particularly in vulnerable groups. 3, 4 Despite this, vaccine effi cacy is considered only moderate and dependent on variables including vaccine type, match between circulating strains and vaccine strains and target age groups. 5 Infl uenza virus is considered highly variable and can evade the immune response in previously vaccinated populations. 6 Current vaccines are designed to induce the production of specifi c antibodies against the viral membrane surface proteins haemagglutinin (HA) of two infl uenza A strains and one or two infl uenza B strains. 3, 6 Variation within the infl uenza virus, due to antigenic shift and drift results in the accumulation of amino acid replacements in the HA epitopes, 3, 7 leading to mismatches between the vaccine strains and circulating strains, independently of all the predictions made each year by the World Health Organization (WHO).

Both live and inactivated infl uenza vaccines are available, but the eff ectiveness of these vaccines in the most vulnerable groups is suboptimal. 8 In children, inactivated vaccines also have a reduced eff ectiveness when compared with live attenuated vaccine in some studies but not in others. 5, 9 Strategies to improve infl uenza vaccine effi cacy include adding a second lineage of type B and a high HA dose, are currently applied to licensed vaccine. 6 Other strategies are also described and tested in diff erent phase trials. Inactivated infl uenza vaccine with MF-59 as an adjuvant has been licensed in Canada in young children and the elderly, 10, 11 with studies showing increased immunogenicity of the vaccine in both groups. 12, 13 Alternative options include adding TLR adjuvants like AS01 or fl agellin, adding conserved epitopes from the viral nucleoprotein, the M2e or stalk of HA could yield improved vaccine effi cacy. 14 Genetic vaccines, DNA and RNA based, can also contribute to produce effi cacious infl uenza vaccines, for example, alphavirus-based H7N9 RNA vaccine have shown promising results, 6 although not yet commercially available.

Since the introduction of pertussis vaccines in the 1940−50s, the incidence of pertussis has decreased dramatically in countries where the vaccine is given routinely. The WHO estimated 16 million pertussis cases in 2008, 95% of those occurring in developing countries. 15 Despite the availability of eff ective prophylactic vaccines against pertussis, there has been a rise in the incidence of disease, with epidemics throughout the world in the last decade. 16 Diff erent reasons have been hypothesized for the outbreaks: waning immunity after vaccination, greater awareness and disease reporting, increased virulence of the bacteria and circulation of new strains. 17 The true burden of disease in industrialised countries may be underestimated with an increased incidence in previously vaccinated populations including older children and the elderly. 18 Adverse reactions such as high fever, severe irritability, hypotonic hyporesponsive episodes and severe local skin reactions were described after administration of the whole cell vaccine (wP). This led to its replacement in developed countries with an acellular, less reactogenic vaccine (aP), fi rst developed in Japan in the 1980s. Several studies have shown that immunity after immunisation with pertussis vaccines, especially after aP, can wane rapidly. A study by Koepke et al. in Wisconsin described the progressive reduction of aP vaccine effi cacy throughout the years (Table 1) . 19 The immune mechanism induced by each vaccine may be responsible for these diff erences. Natural infection or immunisation with wP induces stimulation of T cell immunity, in particular IFN-γ-secreting CD4+ T cells (Th1 and Th17 cells), whereas aP vaccines induce strong antibody responses and Th2-type responses. 20 The baboon model has contributed both to our understanding and the relevance of these immune mechanisms. 21 Following natural infection or vaccination with wP or aP, their immune responses are similar to those observed in humans. 22 There is evidence that the Th17 responses induce clearance of B. pertussis from mucosal surfaces, thereby reducing colonisation and transmission. 23 The lack of Th17 activity following aP vaccination may account for the ongoing disease transmission and resurgence in countries widely using the aP vaccine.

In order to improve aP vaccine effi cacy, possible strategies have been described including the introduction of strains that contain the ptxP3 promoter. These new circulating strains induce higher host production of pertussis toxin (PT), providing a possible selective advantage. 24, 25 The use of new adjuvants, which may or may not be associated with aluminium, can skew the immune response and stimulate a balanced Th1/Th17 response, like CpG oligonucleotides, AS04 (combination of monophosphoryl lipid A and aluminium) and TLR-2 agonists. 20 Interventions such as using modifi ed bacteria virulence factors like adenylate cyclase and tracheal cytotoxin, 26,27 a live nasal attenuated pertussis vaccine (BPZE1) 28 or the use of recombinant pertussis DNA vaccine 29 are also being studied.

There have been various eff ective methods employed for HIV prevention, but many challenges remain to the development of a successful vaccine. There is uncertainty about what the protective functional response is since there is no natural recovery from infection, although long-term survival is 11.9 (−11.1 to 30.1) possible. 30 Broadly neutralizing antibodies develop, but occur late in natural infection 30 and a successful vaccine would need to induce a more rapid response. Dissemination from the mucosal site of infection takes place within 24−72 hours, and any protective response would therefore have to rapidly neutralize the virus at the mucosal surface or kill all HIV-infected cells throughout the body. As with many vaccines, a HIV vaccine would have to overcome strain variation − there are currently 9 genetically distinct clades (subtypes) of HIV-1 and signifi cant variation within clades also occurs. 31 Previous trials have adopted a variety of approaches to obtain the right functional response. Early trials focused on eliciting neutralizing anti bodies targeting the gp120 envelope protein. 32 Subsequent trials have utilized viral vectors to deliver HIV antigens, including adenovirus-5 and canarypox virus. 32 These have aimed to induce protective cellular immune responses, and have included prime-boost strategies using DNA encoding HIV proteins followed by recombinant proteins. Only one study has demonstrated protective vaccine effi cacy, combining a canarypox vector vaccine prime with booster injections of a gp120 subunit vaccine in Thailand. 33 There was 31% reduction in HIV acquisition due to induction of IgG3 antibodies directed against the V1V2 region of gp120 mediating antibodydependent cellular cytotoxicity (ADCC), 34, 35 although effi cacy was high early after vaccination and declined over time.

The importance of such non-neutralizing antibodies has been shown with other pathogens, most notably infl uenza where infection and inactivated vaccine induce ADCC (with strain cross-reactive antibodies. 36, 37 Future strategies for HIV will focus on the induction of broadly neutralizing antibodies via use of envelope trimer structures, which are more immunogenic than monomers, use of better vectors or adjuvants to improve on the induction of ADCC observed in the Thailand trial and induction of eff ector CD8+ memory T cells directed against non-canonical epitopes using persistent viral vectors. This latter strategy was eff ective in clearance of simian immunodefi ciency virus in rhesus macaques, using a CMV vector, and this may be a useful strategy for HIV and other chronic infections. 38

The highest burden of severe, symptomatic rotavirus disease is in 3 to 24 month old children. 39 The impact on childhood mortality is signifi cant in developing countries, whilst there is much morbidity in industrialised countries. Longitudinal studies identifi ed that children naturally infected with rotavirus developed adaptive immunity to prevent primary infection and to protect against re-infection, in particular those causing severe disease. 40−42 Therefore, the principle of administering oral live attenuated rotavirus strains was developed. Currently, monovalent human G1 vaccine Rotarix ® and pentavalent human-bovine re-assortment vaccine Rotateq ® are the most widely used rotavirus vaccines globally.

The effi cacy of these vaccines is very high in industrialised countries. 43, 44 Since their introduction in the U.S. in 2006, there has a been a reduction in hospitalisation and emergency department presentations, all-cause diarrhoea attendance, and rotavirus hospitalisation in unvaccinated individuals, suggesting some degree of indirect protection. 43, 45 However, lower effi cacy has been well documented in many developing countries, clearly noting that vaccine effi cacy has an inverse relationship with childhood mortality. 46 The reasons for this are unclear, proposed explanations include the presence of transplacental and breast milk derived IgA having a neutralising eff ect, concomitant poor nutrition or chronic helminth infections suppressing immune response. 47, 48 However, the microbiota is increasingly implicated in immunological development and modulation of infant mucosal immunity, but the mechanisms remain poorly understood, although microbial interference and zinc defi ciency appear the most important.

Disturbance of the resident microbiota with antibiotics in mice results in reduced susceptibility to poliovirus infection and reduced infectivity of rotavirus. 49, 50 Interestingly, treatment with ampicillin and neomycin before and during oral rotavirus inoculation produced a longer duration and higher titres of serum and faecal IgA compared with untreated controls. 49 These intriguing fi ndings raise many further questions about the impact of microbiome composition on mucosal immunity and methods of immunomodulation (e.g. probiotics, antibiotics) that could improve vaccine effi cacy, in particular in developing countries with high mortality from rotavirus infection.

The diffi culty in development of a successful dengue vaccine lies in the pathogenesis of dengue hemorrhagic fever, the most severe dengue syndrome. There are four dengue virus serotypes, 1−4 and infection results in the development of long-lasting serotype-specifi c antibodies 51,52 which contribute to protection. While infection results in lifelong protection against the infecting serotype, there is only temporary cross-protection to other serotypes. Waning of cross-neutralizing antibodies later renders an individual more susceptible to severe dengue in the event of infection with a serotype diff erent to the previous infection. 53 −57 There is currently only one licensed dengue vaccine, CYD-TDV, which has been registered for use in endemic areas in individuals aged between 9 and 45 years. CYD-TDV is a tetravalent vaccine which includes four live, recombinant chimeric viruses with the prM (membrane) and E (envelope) proteins from each dengue virus serotype inserted separately into the yellow fever 17D genome. The vaccine has been evaluated in clinical trials in Asia and South America in over 30,000 participants, and had an overall effi cacy of 57−61%, 58,59 inducing antibody to each serotype. Effi cacy varied depending on serotype, with highest effi cacy against serotypes 3 (74−78%) and 4 (75−78%), and lowest against serotype 2 (35−42%). A number of explanations for the diff ering serotype-specifi c effi cacies have been suggested, including diff erent exposure doses with diff erent serotypes, diff ering levels of antibodies needed for protection against diff erent serotypes, a diff erence in the pathogenesis of serotype 2 (such as more rapid infection of monocytes or poor replication) or an alteration in the conformation of the envelope protein in the chimeric vaccine for serotype 2. 60 The major safety concern was a fi nding that children aged 2−5 years had an increased risk of hospitalization when more than two years post-vaccination, which may S5 be due to an antibody enhancement eff ect similar to that seen with wild type infections with diff erent serotypes. Vaccination is recommended by the SAGE committee of WHO beginning at 9 years of age and only in those countries where the population is likely to have been infected by one or more dengue serotypes by that age. Future studies will clarify if there is any danger to seronegatives, particularly children.

Human cytomegalovirus (CMV) is a DNA Herpesvirus. The prevalence of seropositivity in the adult population is high and the virus is responsible for lifelong latent infections. Despite high seropositivity, CMV congenital infections due to primary infection or reinfection are a reality and no eff ective preventive strategies are currently available. In the infected population, reactivation normally occurs in the immunocompromised host and is associated with severe outcomes. 61 In whole organ or stem cell transplant recipients, CMV infection is considered one of the most common with associated acute infections and long term indirect eff ects, that could contribute to allograft injury and subsequent graft loss. 62 The implementation of a CMV vaccine could decrease the disease burden with a signifi cant economic impact. 63 Several vaccine candidates are under development. One of the fi rst CMV vaccines, widely tested in humans, particularly in renal transplant patients, was developed by Stanley Plotkin's laboratory, one of the authors of this paper. 64 It contained the Towne strain, and reduced severe disease in seronegative renal transplant patients, although the results were not considered signifi cant for infection. 65 However, the vaccine was not successful in protecting seronegative mothers from acquiring infection from their young children. 66 More recently sub-unit vaccines have been developed. Glycoprotein B (gB) antibodies are specifi c and present in all CMV seropositive individuals. 67 They are currently used in new vaccine design and include the gB/ MF59 adjuvant, gB/Canarypox vector and DNA vaccines gB/pp65/IE1 Trivalent DNA vaccine and gB/pp65 Bivalent DNA vaccine. 68, 69 Other CMV vaccine candidates include: replication-defective CMV strains, soluble pentamer proteins, replication-defective adenovirus vectors, alphavirus replicons, dense bodies and self-replicating RNA vaccines. 70

Respiratory syncytial virus (RSV) is the most important cause of infant hospitalisation in developed countries and globally is responsible for the most deaths in infants after malaria, clearly there is an urgent need for eff ective vaccine development. 71 In the 1960s, formalin-inactivated RSV (FI-RSV) vaccines did not protect from primary RSV infection, and paradoxically resulted in more severe clinical disease, in particular in young vaccinated children. 72, 73 This FI-RSV vaccine failed due to alterations in the fusion (F) protein during formalin treatment that resulted in an imbalanced host response with immune complex deposition and Th2 skewing. 74 The F glycoprotein remains the main antigenic target for RSV vaccine development, due to its role in host cell viral entry, conservation across both A and B subtype and the ability of anti-F passive monoclonal antibodies (palivizumab) to prevent severe disease in RSV naïve infants. 75 In human sera, the neutralising activity of Pre-F (metastable) epitopes is much greater than Post-F (stable), requiring an intricate understanding of the atomic-level protein structure in order to stabilise this for conversion into vaccine candidates. Using Pre-F-specifi c monoclonal antibodies (D25, 5C4, AM22) to bind to Pre-F, the crystal structure was visualised, identifying novel antigenic sites not available on Post-F due to conformational changes occurring on membrane fusion to allow viral entry (Figure 1 ). 76 Optimal stabilisation of Pre-F was achieved by insertion of cysteine residues to form disulphide bonds and cavity fi lling mutations, resulting in a stable Pre-F DS-Cav1 which induced potent neutralising antibodies in mice and macaques. 76 These molecular approaches are rapidly being applied to synthetic vaccine development for the identifi cation of suitable candidate antigens, and the understanding of the B cell repertoire 77 leading to structural antigen modifi cations. 78 The effi cacy of current Pre-F vaccines in clinical trials is yet to be demonstrated.

Many RSV vaccines are in clinical trials, but due to the previous safety concerns and impact of passive maternal antibody on vaccine effi cacy, direct protection of infants is not the priority. Alternative vaccine strategies involve immunisation of pregnant women to passively transfer neutralising antibodies to protect the infant up to 3−4 months of age, immunisation of older children to protect them and to disrupt transmission, and immunisation of the elderly to provide direct protection to this vulnerable group. 75 Other approaches showing promise in clinical trials include extended half-life monoclonal antibodies, directed against prefusion F proteins. These potentially provide passive immunity through one intramuscular dose per season, for healthy and high-risk infants in their fi rst RSV season. 79

There are several aspects relating to vaccine design and understanding vaccine-induced immunity which will be important to investigate in the coming years. A number of new technologies are being developed in pre-clinical studies to improve future vaccines, such as DNA plasmids with or without electroporation, 80 self-amplifying mRNA molecules 81 and vaccines which are better able to activate dendritic cells. The non-specifi c eff ects of vaccines are far from being understood and may have consequences which reach beyond the fi eld of vaccinology if vaccine antigens are able to shape the immune system in early life. 82 . The reduction in speed and cost of genetic sequencing means that it is will become easier to use genetic information from vaccinated individuals to better predict immunogenicity and reactogenicity of vaccines, which will aid future vaccine design. Persistence of vaccine-induced protection remains an issue, with almost all vaccines requiring multiple doses. This may be improved in future by better understanding the role of follicular T cells in induction of protective responses, with IL-7 possibly having a role in improving persistence of protection. 83 Most pathogens have multiple virulence antigens which could be included in vaccines, and understanding the natural immune response to these, and the diff erence in responses between individuals during infection will aid antigen selection. Identifi cation of conserved epitopes may help design vaccines with 'universal' protection against a pathogen, although this has been diffi cult to achieve to date. Some vaccines still do not have a defi ned correlate of protection, and newer systems biology approaches may be able to characterize these, which are likely to be complex and dependent on a number of factors rather than a single cut-off value in an antibody assay. Better adjuvants are required to improve responses in immature immune systems (such as infants and the immunocompromised), specifi cally stimulate selective responses (such as Th1, Th2, Th17) and generate T cell immunity in the absence of vaccine replication.

Financial constraints on pharmaceutical companies may result in reduced vaccine development and production. With national public health bodies not stipulating their priorities to industry developers, combined with the time frame for conception to licensure, there is an inevitable delay and lack of cohesion. There is a further lack of enthusiasm and economic incentive for the investment into vaccines for emerging diseases such as fl aviviruses (Zika, West Nile), haemorrhagic fevers (Ebola, Marburg, Lassa) or coronaviruses (MERS, SARS). However, the expansion of the Developing Countries Vaccine Manufacturing Network to encourage sustainable and aff ordable vaccine production and the recent changes in patent protection for drug manufacture in developing regions may help to ameliorate some of these issues.

Collective responsibility in response to recent large-scale global epidemics, led to the establishment of the Coalition for Epidemic Preparation and Innovation in January 2016. This multi-faceted partnership involving government, industry, civil bodies and foundations will focus on vaccine development for potential epidemic infections. The challenges lie in prioritising infections, organising the development and manufacturing processes and obtaining sustainable funding arrangements from governments and foundations.

For the host, vaccinations must be safe, with minimal side eff ects, must provoke immune responses with specifi city and memory to induce long-lasting protection which can ideally be quantifi ed. The context in which the vaccinee resides may impact on the ability to respond to the vaccine antigens because of demographic or environmental conditions. Vaccine antigens should be able to capture the diversity of the pathogenic organism, have well-defi ned structures and methods of enhancing recognition by the host and be ultimately easily reproducible for mass production. Hostpathogen interactions at the molecular and cellular level will play an important role in the development of future vaccines. We continue to aspire to developing vaccines with excellent immunogenicity in the extremes of age, to protect against the diverse array of pathogenic organisms, and which ultimately should be available to all populations.

CMCR and MVP have no confl icts of interest. MS has been an investigator on grants awarded from Pfi zer, but has received no personal payment. SP is a paid consultant to most major vaccine manufacturers and to a number of biotechnology companies working on vaccine development.

Jenner's inquiry after 200 years

A universal vaccine for serogroup B meningococcus

Toward a Universal Infl uenza Virus Vaccine: Prospects and Challenges

Eff ectiveness and harms of seasonal and pandemic infl uenza vaccines in children, adults and elderly

Seasonal infl uenza vaccine effi cacy and its determinants in children and nonelderly adults: A systematic review with meta-analyses of controlled trials

Infl uenza Vaccines: A Moving Interdisciplinary Field

Hemagglutinin Receptor Binding Avidity Drives Infl uenza A Virus Antigenic Drift

Immunologic correlates of protection and potential role for adjuvants to improve infl uenza vaccines in older adults

The relative effi cacy of trivalent live attenuated and inactivated infl uenza vaccines in children and adults

Product Monograph

Canadian Immunization Guide Chapter on Infl uenza and Statement on Seasonal Infl uenza Vaccine for

Dissecting the Immune Response to MF59-adjuvanted and Nonadjuvanted Seasonal Infl uenza Vaccines in Children Less Than Three Years of Age

Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a nonadjuvanted seasonal infl uenza vaccine in elderly subjects

Increasing Complexity of Vaccine Development

World Health Organisation. Pertussis vaccines: WHO position paper

Pertussis cases rise 10-fold among older children and adults in England and Wales

Seroprevalence of Pertussis in the Netherlands: Evidence for Increased Circulation of Bordetella pertussis

Societal Costs and Morbidity of Pertussis in Adolescents and Adults

Estimating the Eff ectiveness of Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) for Preventing Pertussis: Evidence of Rapidly Waning Immunity and Diff erence in Eff ectiveness by Tdap Brand

Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity

The baboon model of pertussis: eff ective use and lessons for pertussis vaccines

Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model

Protective role of Th17 cells in pulmonary infection

Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis

Genomic Analysis of Isolates From the United Kingdom 2012 Pertussis Outbreak Reveals That Vaccine Antigen Genes Are Unusually Fast Evolving

Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines

The Virulence Factors of Bordetella pertussis: Talented Modulators of Host Immune Response

A Phase I Clinical Study of a Live Attenuated Bordetella pertussis Vaccine − BPZE1; A Single Centre, Double-Blind, Placebo-Controlled, Dose-Escalating Study of BPZE1 Given Intranasally to Healthy Adult Male Volunteers

Granulocyte-macrophage colony-stimulating factor DNA prime-protein boost strategy to enhance effi cacy of a recombinant pertussis DNA vaccine

HIV infection: epidemiology, pathogenesis, treatment, and prevention

Update on HIV-1 diversity in Africa: a decade in review

Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines

Antibody-Dependent Cellular Cytotoxicity Is Associated with Control of Pandemic H1N1 Infl uenza Virus Infection of Macaques

Generation and Protective Ability of Infl uenza Virus-Specifi c Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge

Immune clearance of highly pathogenic SIV infection

Rotavirus vaccines: an overview

Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children

Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa

Rotavirus infections in infants as protection against subsequent infections

Eff ectiveness and impact of rotavirus vaccines in the United States −

Rotavirus vaccine and health care utilization for diarrhea in U.S. children

Summary of eff ectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries

Wor ld Health Organisation. Rotavirus vaccines: an update

Rotavirus vaccination in developing countries

Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR

Antibiotic treatment suppresses rotavirus infection and enhances specifi c humoral immunity

Intestinal microbiota promote enteric virus replication and systemic pathogenesis

Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype

Neutralization of dengue virus in the presence of Fc receptormediated phagocytosis distinguishes serotype-specifi c from cross-neutralizing antibodies

Symptomatic versus inapparent outcome in repeat dengue virus infections is infl uenced by the time interval between infections and study year

Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity

Prospective cohort studies of dengue viral transmission and severity of disease

A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995−1996

Risk factors in dengue shock syndrome

Clinical effi cacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

Effi cacy of a tetravalent dengue vaccine in children in Latin America

Immunodominant Dengue Virus-Specifi c CD8+ T Cell Responses Are Associated with a Memory PD-1+ Phenotype

Expanding role of cytomegalovirus as a human pathogen

Revisiting the eff ects of CMV on long-term transplant outcome

Vaccine Development to Prevent Cytomegalovirus Disease: Report from the National Vaccine Advisory Committee

Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants

Multicenter trial of towne strain attenuated virus vaccine in seronegative renal transplant recipients

Immunity Induced By Primary Human Cytomegalovirus Infection Protects Against Secondary Infection Among Women Of Childbearing Age

Enveloped Virus-Like Particle Expression of Human Cytomegalovirus Glycoprotein B Antigen Induces Antibodies with Potent and Broad Neutralizing Activity

Desirability and feasibility of a vaccine against cytomegalovirus

The history of vaccination against cytomegalovirus

RSV vaccine use − the missing data

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

A role for immune complexes in enhanced respiratory syncytial virus disease

Novel antigens for RSV vaccines

Structure of RSV fusion glycoprotein trimer bound to a prefusion-specifi c neutralizing antibody

Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design

Recent advances in the molecular design of synthetic vaccines

Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection

Using Plasmids as DNA Vaccines for Infectious Diseases

Recent innovations in mRNA vaccines

Harnessing the benefi cial heterologous eff ects of vaccination

Intranasal Introduction of Fc-Fused Interleukin-7 Provides Long-Lasting Prophylaxis against Lethal Infl uenza Virus Infection

Protein Crystallography in Vaccine Research and Development